Mabwell (Shanghai) Bioscience Co., Ltd. Class H AI Stock Analysis
Want to see HK:2493 full AI Analyst Report?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) AI Stock Analysis
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
(HKEX:2493)
Overall score is constrained primarily by weak financial performance (declining revenue, large operating losses, high leverage, and sustained negative operating/free cash flow). Technicals add additional pressure with price below key moving averages and negative MACD, while valuation remains unattractive due to negative earnings and no dividend support.
Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 9.61B
- Dividend Yield
- ―
- Average Volume (3M)
- 191.64K
- Price to Earnings (P/E)
- -5.8
- Beta (1Y)
- 0.03
- Revenue Growth
- 20.87%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 1,325
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Mabwell (Shanghai) Bioscience Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectio...
How the Company Makes Money
Mabwell (Shanghai) Bioscience Co., Ltd. generates revenue primarily through (1) sales of commercialized drug products, if and when its biologics receive regulatory approval and are launched; and (2) collaborations and out-licensing activities related...
Mabwell (Shanghai) Bioscience Co., Ltd. Class H Financial Statement Overview
Summary
Financial profile is high-risk: TTM revenue declined 17.9%, profitability remains deeply negative (TTM net margin about -108%), leverage is elevated (TTM debt-to-equity ~3.84x), and cash burn persists (TTM operating cash flow ~-935M; free cash flow ~-1.04B). Offsetting positives are a strong gross margin (~74.5%) and some improvement versus the worst historical loss intensity and leverage peak.
Income Statement
22NegativeBalance Sheet
28NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 717.92M | 662.52M | 199.78M | 127.84M | 27.73M | 15.96M |
| Gross Profit | 533.74M | 598.05M | 170.83M | 126.47M | 27.66M | -72.92M |
| EBITDA | -819.99M | -647.88M | -844.97M | -937.63M | -858.54M | -699.62M |
| Net Income | -1.05B | -969.33M | -1.04B | -1.05B | -955.23M | -756.86M |
Balance Sheet | ||||||
| Total Assets | 5.30B | 4.56B | 4.28B | 4.46B | 4.62B | 1.59B |
| Cash, Cash Equivalents and Short-Term Investments | 2.32B | 1.53B | 1.20B | 1.67B | 2.55B | 96.37M |
| Total Debt | 3.69B | 2.60B | 2.07B | 1.26B | 752.83M | 333.98M |
| Total Liabilities | 4.40B | 4.02B | 2.72B | 1.88B | 1.11B | 574.15M |
| Stockholders Equity | 715.70M | 349.51M | 1.57B | 2.58B | 3.52B | 1.01B |
Cash Flow | ||||||
| Free Cash Flow | -1.04B | -447.93M | -1.29B | -1.28B | -1.26B | -624.47M |
| Operating Cash Flow | -934.77M | -290.22M | -956.44M | -782.73M | -719.17M | -410.56M |
| Investing Cash Flow | -175.13M | -199.31M | -291.55M | -509.62M | -602.80M | 7.77M |
| Financing Cash Flow | 2.00B | 791.92M | 831.70M | 444.94M | 3.72B | 195.65M |
Mabwell (Shanghai) Bioscience Co., Ltd. Class H Peers Comparison
Overall Rating
HK:269664.6Neutral
HK:180163Neutral
HK:996645Neutral
HK:992644.7Neutral
HK:249342Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | HKD 23.70B | 23.23 | 20.41% | ― | 32.63% | 8.74% | |
| 63Neutral | HKD 145.95B | 100.26 | 6.06% | ― | 42.64% | 9.67% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | HKD 5.19B | -26.28 | -10.27% | ― | -31.77% | -177.01% | |
| 45Neutral | HKD 55.53B | -48.14 | -10.86% | ― | 42.47% | -15.80% | |
| 42Neutral | HKD 9.54B | -5.80 | -205.41% | ― | 20.87% | ― | |
| 41Neutral | HKD 27.62B | -63.59 | -7.23% | ― | 35.82% | 54.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2493 | Mabwell (Shanghai) Bioscience Co., Ltd. Class H | 17.67 | -10.13 | -36.44% | |
| HK:1801 | Innovent Biologics | 83.50 | -8.70 | -9.44% | |
| HK:9926 | Akeso, Inc. | 59.00 | -54.10 | -47.83% | |
| HK:9966 | Alphamab Oncology | 5.33 | -4.98 | -48.30% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 13.92 | -10.64 | -43.32% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 43.46 | -24.14 | -35.71% |
Mabwell (Shanghai) Bioscience Co., Ltd. Class H Corporate Events
Mabwell Issues Unaudited PRC-Standard Q3 2026 Results and Cautions Investors
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical group listed in Hong Kong and on Shanghai’s STAR Market, has released its unaudited 2026 third-quarter financial report prepared under PRC accounting standards. The board and senior managem...
Mabwell Showcases Promising ADC Breast Cancer Data as 9MW2821 Advances Across Pivotal Trials
Mabwell (Shanghai) Bioscience Co., Ltd. announced that Phase II clinical data for its innovative Nectin-4-targeted ADC 9MW2821 in patients with locally advanced or metastatic triple-negative breast cancer previously treated with topoisomerase I inhib...
Mabwell Schedules Board Meeting to Approve Third-Quarter Results
Mabwell (Shanghai) Bioscience Co., Ltd., a Hong Kong-listed bioscience and biopharmaceutical company, operates through a group structure in the PRC with a board that includes both executive and independent non-executive directors. The firm targets th...
Mabwell Shareholders Back SynuSight Deals and Business Scope Change
Mabwell (Shanghai) Bioscience Co., Ltd. announced that its 2026 fourth extraordinary general meeting was duly convened in Shanghai and all directors attended, with legal advisers confirming compliance with PRC laws and the company’s articles. Shareho...
Mabwell Reports Positive COPD Data for 9MW1911 Ahead of ERS 2026
Mabwell (Shanghai) Bioscience Co., Ltd. will present updated Phase Ib/IIa clinical data for its innovative monoclonal antibody 9MW1911 in former smokers with moderate-to-severe COPD at the European Respiratory Society Congress 2026 in Barcelona. The...
Mabwell Narrows Interim Loss as Revenue Surges in First Half of 2026
Mabwell (Shanghai) Bioscience Co., Ltd. reported a sharp rise in interim revenue to RMB312.45 million for the six months ended June 30, 2026, up from RMB101.10 million a year earlier. Despite this strong top-line growth, the company remained loss-mak...
Mabwell Plans Expanded Business Scope and Governance Update
Mabwell (Shanghai) Bioscience Co., Ltd. has approved resolutions to significantly expand and refine its business scope to cover a broad range of technical services, medical and agricultural research, genetic diagnosis and cell technology, as well as...
Mabwell Calls Extraordinary Meeting to Approve SynuSight Deals and Business Scope Change
Mabwell (Shanghai) Bioscience Co., Ltd. has convened its fourth extraordinary general meeting for 2026 to seek shareholder approval on key business resolutions, including entering into a license agreement with SynuSight and jointly applying for a sci...
Mabwell Sets Board Meeting to Approve 2026 Interim Results
Mabwell (Shanghai) Bioscience Co., Ltd., a PRC-based biopharmaceutical group listed in Hong Kong under stock code 2493, develops and commercializes bioscience innovations, supported by a board comprising executive and independent non-executive direct...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
